2020

06.05.2020 – IGEA Pharma N.V.

Miami University confirms high quality of IGEA's COVID-19 rapid test

IGEA Pharma N.V. / Key word(s): Miscellaneous
Miami University confirms high quality of IGEA's COVID-19 rapid test

06-May-2020 / 05:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Miami University confirms high quality of IGEA's COVID-19 rapid test

Hoofddorp, the Netherlands, 6 May 2020. IGEA Pharma N.V. (SIX: IGPH) today
announced that an evaluation by the Histocompatibility Laboratories,
Department of Surgery, University of Miami - Miller School of Medicine
suggests that the IGEA's COVID-19 antibody rapid test appears to be superior
to an established ELISA procedure in detecting IgM and IgG antibodies.

Furthermore, an overall higher sensitivity of the IGEA's rapid test over the
ELISA procedure used has been observed using a RT PCR test comparison for
the same specimens, and the PCR results comparison could suggest suitability
in using the antibody-based test even in early stages of the infection.

Vincenzo Moccia, CEO of IGEA: "This is a key step in proving reliability of
the IGEA's COVID-19 antibody-based test to the market. We hope now to
consolidate such evidence with a positive and soon response to our
submission EUA 200192 filed with the FDA on 6 April 2020 and start selling".

According to previous disclosures, IGEA has ensured the exclusivity of the
antibody-based test under certain volume-based conditions for the US States
New York, California, and Louisiana.

***

About IGEA
IGEA Pharma focuses on health-tech and med-tech products and devices.
Health-tech products are exclusively preventative. IGEA commercializes an
Alzheimer's prevention set (which includes 'Alz1', an at-home lab test kit
to measure non-bound copper in the blood and 'Alz1 Tab', a natural dietary
supplement designed to reduce blood heavy metals content), and expects to
launch a diabetes type II prevention set in 2020. Non-ceruloplasmin bound
copper is an expected Alzheimer's and diabetes type II associated biomarker.
Determining and regulating non-bound copper can contribute to reduce the
risk of Alzheimer's and diabetes type II. Med-tech products focuses on
selected solutions and specialities. IGEA operates in air and inanimate
environmental surface sanitization with aerosol technology-based devices and
expects to start commercializing polymeric based medical bags and other
specialty devices for medical use during 2020.

IGEA is listed on the SIX Swiss Exchange (ticker IGPH) and is headquartered
in Hoofddorp, the Netherlands. Find out more at www.igeapharma.nl

Contacts
Vincenzo Moccia, CEO, +39 340 583 09 33, moccia@igeapharma.com
Patrick Pozzorini, CFO, +41 79 314 41 43, pozzorini@igeapharma.com

Disclaimer
This document constitutes neither an offer to buy nor to subscribe
securities and neither this document nor any part of it should form the
basis of any investment decision in IGEA.

The information contained in this press release has been carefully prepared.
However, IGEA bears and assumes no liability of whatever kind for the
correctness and completeness of the information provided herein. IGEA does
not assume an obligation of whatever kind to update or correct information
contained in this press release whether as a result of new information,
future events or for other reasons.

This publication may contain specific forward-looking statements and
assessments or intentions concerning IGEA and its business. Such
forward-looking statements are subject to known and unknown risks,
uncertainties and other factors which may result in a substantial divergence
between the actual results, financial situation, development or performance
of IGEA and those explicitly or implicitly presumed in these statements.
Against the background of these uncertainties, readers should not rely on
forward-looking statements. IGEA assumes no responsibility to update
forward-looking statements or to adapt them to future events or
developments, except as may be required by law.


---------------------------------------------------------------------------

End of ad hoc announcement

---------------------------------------------------------------------------

close